ESMO 2018 | The importance of HCPs feeling comfortable and confident with biosimilars

Justin Stebbing, MD, from Imperial College London, London, UK, gives an overview of the importance of healthcare professionals and patients feeling comfortable with trastuzumab biosimilars. Prof. Stebbing expresses that these drugs are safe and are equivilant to the refereance molecules in randomized Phase III clinical trials, and therefore people must be increasingly confident in using them. He explains that we must ensure that the supply chain is adequate, and that pharmacists and patients are comfortable with supplying and receiving the drugs. Furthermore, it is important that patients are told by doctors and nurses that there may be some substitution and interchangability within the hospitals, so that they understand what they are receiving and why. This interview was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany.